Ginkgo Bioworks Reports 49% Revenue Decline, Q1 Loss; $47M Cash Restricted Post-Quarter

summarizeSummary

Ginkgo Bioworks reported a substantial 49% year-over-year revenue decrease in Q1 2026, alongside a net loss, and disclosed that $47 million in cash was restricted in April 2026, further impacting liquidity.

check_boxKey Events

• Revenue Plunge

  Q1 2026 revenue from continuing operations decreased by 49% year-over-year to $19.5 million, primarily due to a contract termination and reduced scope with a large agriculture customer.

• Net Loss Reported

  The company reported a net loss of $82.6 million for Q1 2026, an improvement from $91.0 million in Q1 2025, largely influenced by the Biosecurity divestiture and reduced restructuring charges.

• Liquidity Impacted by Restricted Cash

  Post-quarter, in April 2026, $47.0 million in cash and cash equivalents became restricted to secure a surety bond, reducing available liquidity.

• Operating Cash Burn Increased

  Net cash used in operating activities from continuing operations increased to $46.4 million in Q1 2026 from $42.7 million in Q1 2025.

auto_awesomeAnalysis

Ginkgo Bioworks reported a substantial 49% year-over-year revenue decrease, indicating significant challenges in its core business following a contract termination and reduced customer scope. While the net loss improved, this was largely due to the Biosecurity divestiture and the conclusion of major restructuring, rather than a fundamental improvement in operating profitability. The increase in operating cash burn, coupled with the post-quarter restriction of $47.0 million in cash for a surety bond, raises significant questions about the company's cash runway, despite management's assertion of sufficient funds for the next 12 months. Investors should closely monitor future revenue trends and the company's ability to manage its cash burn and secure additional non-dilutive funding. The write-off of the Bolt Threads note also highlights risks in the company's investment portfolio.